The evaluation of the therapeutic response with a 20-year follow-up and the progress made in residual disease monitoring with the quantification of the chimeric BCR-ABL transcript have allowed standardizing CML management [5]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.